IntelliCyt Corporation Announces Shipment of New Instrument and Expansion of Reagent Portfolio for Drug Discovery Screening

Share Article

iQue® Screener HD and MultiCyt® Dye and Bead Reagents bring cell health and cell function assays to Phenotypic Screening.

IntelliCyt Corporation, a leading provider of high throughput cell- and bead-based screening solutions, announces the shipment of iQue® Screener HD. Breaking new ground in the miniaturization of suspension assay formats, the iQue Screener HD is the first and only commercially available instrument that can process, analyze, and visualize data from 1536 well microplates. The company also announces the availability of new MultiCyt® reagents to profile cell health and monitor cell function.

“The iQue Screener HD is the latest addition to IntelliCyt’s High Throughput Flow platform of instrumentation, software and application-specific reagents. Advanced sampling, processing, and analysis technologies were incorporated to overcome the evaporation and sample re-suspension challenges of assays in 1536 well microplates,” commented Terry Dunlay, CEO at IntelliCyt. “The iQue HD fits seamlessly in the laboratory automation environment, runs unattended, and handles tens of millions of data points per high density plate in seconds.”

Additionally, three new reagent sets are expanding the MultiCyt family of products. Membrane Integrity and Cell Proliferation dye panels now join Apoptosis and Cell Cycle reagents to provide a suite that can be multiplexed to provide high-content, cell-health profiles. A new panel of streptavidin coated capture beads, QBeads™ SAv, give users the flexibility to screen their custom targets of choice while retaining multiplexing with the existing QBeads product line. MultiCyt reagents are designed for “no-wash” assay preparation and can be run in very low volume formats, saving time and money.

About IntelliCyt Corporation

IntelliCyt Corporation develops cell- and bead-based screening solutions using High Throughput Flow technology for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

R. Terry Dunlay, President and CEO
since: 08/2012
Like >
IntelliCyt Corporation

Follow us on
Visit website